Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lyt-100 (Deupirfenidone) vs Pirfenidone in Healthy Older Adults
NCT07456800Phase 1Completed
- Sponsor
- PureTech Health
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deupirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by PureTech Health. Primary endpoints: Maximum Plasma Concentration at 14 days, Area Under the Curve at 14 days and 2 more. Started Jul 2021; status: completed.
02
Drugs
deupirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07456800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456800.